Responsiveness to change in health status of the EQ-5D in patients treated for depression and anxiety

Kenneth Sandin (✉ ksandin@gmail.com)

Diakonhjemmet Hospital: Diakonhjemmet Sykehus AS <https://orcid.org/0000-0002-1673-9606>

Gemma Shields

The University of Manchester Manchester Centre for Health Economics

Ragne Gunnarsdotter Hole Gjengedal

Diakonhjemmet Hospital: Diakonhjemmet Sykehus AS

Kåre Osnes

Diakonhjemmet Hospital: Diakonhjemmet Sykehus AS

Marianne Tranberg Bjørndal

Diakonhjemmet Hospital: Diakonhjemmet Sykehus AS

Silje Endresen Reme

University of Oslo: Universitetet i Oslo

Odin Hjemdal

Norwegian University of Science and Technology: Norges teknisk-naturvitenskapelige universitet

Research article

Keywords: Self-rated health, depression, anxiety, EQ-5D, responsiveness

Posted Date: July 13th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-701769/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Purpose

The EQ-5D is a commonly used generic measure of health but evidence on its responsiveness to change in mental health is limited. This study aimed to explore EQ-5D responsiveness in patients receiving treatment for depression and anxiety.

Methods

Patient data ($N = 416$) were collected at baseline and at end of treatment in an observational study in a Norwegian outpatient clinic. Responsiveness in the EQ-5D was compared to change in the Beck Depression Inventory-II (BDI-II) and the Beck Anxiety Inventory (BAI). Effect sizes (Cohen's d), Standardised response mean (SRM), and Spearman's correlation were calculated. Patients were classified as "Recovered", "Improved", or "Unchanged" during treatment using the BDI-II and the BAI. ROC analyses determined whether the EQ-5D could correctly classify patient outcomes.

Results

Effect sizes were large for the BAI, the BDI-II, the EQ-5D value and the EQ VAS, ranging from $d = 1.07$ to $d = 1.84$. SRM ranged from .93 – 1.67. Spearman's correlation showed moderate agreement between the EQ-5D value and the BDI-II ($r_s = -.48$), and the BAI ($r_s = -.41$). The EQ-5D consistently identified "Recovered" patients versus "Improved" or "Unchanged" in the ROC analyses with AUROC ranging from .72 – .84.

Conclusion

The EQ-5D showed good agreement with clinical measures evaluating symptom change, and correctly identifying recovered patients. These findings indicate that the EQ-5D may be appropriately responsive to change in patients with depression and anxiety disorders, although replication in other clinical samples is needed.

Plain English Summary

The EQ-5D is a questionnaire that people fill in to report their subjective health. It is often used in clinics or hospitals to better understand how patients are affected by their illnesses, and if their health improves after treatment. For this information to be trustworthy, we need to verify how accurately the EQ-5D measures health for the particular patients we want to use it with. This is often done by comparing EQ-5D scores with scores from other questionnaires. For example, if we want to use the EQ-5D with a group of patients with depression, we compare the scores of the EQ-5D with scores from questionnaires that are commonly used to measure depression symptoms.

In this study, we compared the scores of the EQ-5D with scores from questionnaires measuring symptoms of depression and anxiety. Their performances were similar, and the EQ-5D scores could also correctly identify which patients had recovered during treatment. This implies that the EQ-5D can be a useful tool for understanding the impact of depression and anxiety and can help in decision-making regarding these patients.

Introduction

One out of every two people will experience a mental health problem during their lifetime and mental ill health is a leading cause of global disease burden [1]. Between 2010 and 2030, mental illness is projected to cost \$ 16.1 trillion worldwide, putting it on par with cardiovascular disease [2]. Depression and anxiety disorders account for 40.5 % and 14.6 % of the disability-adjusted life-years that are due to mental illness, making them the most costly mental health problems [3]. This substantial burden may still be underestimated [4], in part because of difficulty in measuring the wide ranging effects these disorders have on health and functioning [5].

At the recommendation of decision-making bodies such as the National Institute of Health and Care Excellence (NICE), generic measures are increasingly used to capture health status [6, 7]. Mental disorders like depression and anxiety have broad, negative impact on quality of life and wellbeing that may not be adequately reflected by condition-specific measures [5, 8]. Generic measures may thus be a valuable supplement to measures of primary symptoms as they capture broader concepts of health. These instruments can also help compare burden of disease and impact of interventions for different patient groups, such as in cost-benefit analyses, making them useful tools for decision-makers, researchers, and clinicians [6]. To adequately fill this role, it must be demonstrated that the generic measure in question can accurately record health status in the relevant patient population.

One of the most commonly used generic measures of self-reported health is the EQ-5D [6]. The EQ-5D records health status across five dimensions: Mobility, Self-care, Usual activities, Pain / discomfort, and Anxiety / depression [6]. The previous version of the EQ-5D used three levels of severity and showed good psychometric properties in depression, but mixed results in anxiety disorders [9]. A recent review evaluated the properties of the newer five-level version of the EQ-5D across multiple patient groups [10]. Three studies of patients with mental health problems were included, showing moderate to good correlation between condition-specific measures and the five-level EQ-5D in cross-sectional designs [11–13].

These studies did not include data on responsiveness [10]. Responsiveness is often defined as an instrument's ability to detect clinically significant change over time [9, 14]. Two criteria have been suggested for defining what constitutes “clinically significant change”: That the magnitude of change be statistically reliable, and that patients end up in a clinical range that renders them indistinguishable from the normal population, i.e. they have recovered [15]. Responsiveness according to these criteria is not a fixed parameter, but will likely vary according to populations and context [16]. This makes it necessary to

investigate responsiveness across multiple patient groups. One study did find reasonable validity and moderate responsiveness in anxiety on the three-level EQ-5D [17]. But only a few studies have examined this aspect of the five-level EQ-5D in depression and anxiety [10].

One such study found that using only the Anxiety/depression dimension of the EQ-5D did not adequately capture responsiveness in anxiety and depression for patients treated in a general internal medicine ward [18]. Another study found that the EQ-5D could adequately screen for depression and anxiety by distinguishing between severity levels in patients with type 2 diabetes. This was true of both the Anxiety/depression dimension and the overall EQ-5D value [19]. However, this was a cross-sectional design, and the ability of the EQ-5D to detect change over time in patients with depression and anxiety is not established, and was specifically targeted by a review of the literature as a future research priority [10]. Investigating this aspect of the EQ-5D is imperative in establishing its usefulness in this patient group, particularly in clinical settings.

To our knowledge, ours is the first study to examine the responsiveness of the five-level EQ-5D in patients treated for depression and anxiety as their primary diagnoses. In line with recommendations and methodology used in previous studies, we explored responsiveness of the EQ-5D by comparing change from start to end of intervention with change in condition-specific measures [16, 18, 19]. The aim of the study was thus to test the following hypotheses: 1) that the EQ-5D shows similar range in effect size and an at least moderate correlation with change scores in condition-specific measures, and 2) that the EQ-5D can identify patients classified as “Recovered” by condition-specific measures at end of treatment.

Methods

Study context

Data were collected at in a naturalistic observational study that ran from May 2017 – March 2020 at the Department of Mental Health and Substance Abuse, Diakonhjemmet Hospital in Oslo, Norway. The clinic is part of the national health service, and the study is part of the project “The Norwegian studies of psychological treatments and work (NOR-WORK)”. Patients are referred by their general practitioners and screened by a clinical psychologist using anamnestic information, the Beck Depression Inventory-II (BDI-II), the Beck Anxiety Inventory (BAI), and the MINI-International Neuropsychiatric Interview [20–22]. Diagnoses are set according to the International Classification of Diseases 10 (ICD-10) [23]. Inclusion criteria for the present study were that the patient was an adult of working age (18–70 years) with clinically significant levels of depression and anxiety operationalised as follows: Patients with a primary depression diagnosis had to have a minimum score of 14 on the BDI-II, and patients with a primary anxiety diagnosis had to have a minimum score of 16 on the Beck Anxiety Inventory BAI. In addition to primary depression or anxiety diagnoses, patients with adjustment disorder and mixed anxiety and depression were included in the study. Adjustment disorder is sometimes referred to as “situational depression”, underlining its close relationship with depressive disorders [23]. Similarly, patients with a

mixed anxiety and depressive disorder were included as the diagnosis is comprised of symptoms of anxiety and depression.

Exclusion criteria were severe mental illness such as bipolar disorder, high risk of suicide, engaging in active substance abuse, or suffering from cluster A or B personality disorder. All patients who signed a written consent form and completed treatment, including filling in questionnaires at baseline and at end of treatment, were included ($N=416$). The current study thus focused on patients who completed treatment.

Patients received either Metacognitive therapy (MCT) or Cognitive behavioural therapy (CBT) according to diagnose specific manuals [24, 25], and average duration of treatment was 10.11 sessions (SD 3.93). Previous research has shown that half the patients are on sick leave when referred, and treatment thus also includes interventions aimed at helping patients return to work [26].

Instruments

Clinical and sociodemographic data were collected at baseline and end of treatment from patient journals and from self-report questionnaires.

The EQ-5D: The EQ-5D questionnaire firstly asks respondents to rate their current health on five dimensions: Mobility, Self-Care, Usual activities, Pain / discomfort, and Anxiety / depression on a severity scale from 1 ("No problems") to 5 ("Severe problems"). The combined severity ratings give an EQ-5D profile, e.g. "11111" in the case of "No problem" on all five dimensions. This health profile can be converted to the EQ-5D value using preference-based weights. A value of 0.00 indicates death and 1.00 indicates perfect health. The EQ-5D value can be used to calculate quality-adjusted life-years (QALYs), i.e. a score of 1.00 for one year equals one QALY. The preference-based weights used to convert responses to EQ-5D values are often referred to as "value sets". A study is underway to acquire a Norwegian set, but is not yet completed [27]. This study used the crosswalk system recommended by NICE for converting EQ-5D profiles to EQ-5D values [28, 29]. For the EQ-5D value, healthy people generally report scores close to 1.00. In a recent survey of the Norwegian general population, the mean EQ-5D value in a postal survey was .848 [30].

The second part of the EQ-5D asks patients to rate their health on a 20 cm visual analogue scale (VAS) where the bottom ("0") indicates worst possible health, and the top ("100") indicates best possible health. Although it is related to the EQ-5D profile and the value scores, it does not measure the same construct. For instance, the EQ VAS score has been shown to decline with age even for people whose EQ-5D profile show no problems ("11111") [6].

The Beck Depression Inventory-II (BDI-II) is a 21 item questionnaire measuring severity of symptoms over the last two weeks on a scale from 0–3, giving a total sum score of 0–63. Examples include feeling sad and change in appetite or sleep. Suggested scoring indicates that 0–13 reflects minimal symptoms, 14–19 mild, 20–28 moderate, and 29–63 severe symptoms [21]. The BDI-II has been found to be psychometrically sound in depression [31], Chronbach's α in the current study was .86.

The Beck Anxiety Inventory (BAI) is a self-report measure of anxiety severity over the last week. As with the BDI-II, anxiety symptoms (e.g. “Heart pounding or racing” or feeling “nervous”) are scored on a severity range from 0–3, giving a total sum score of 0–63. Suggested scoring indicates that 0–15 reflects mild symptoms, 16–25 moderate, and 26–63 severe symptoms. The BAI has demonstrated good psychometric properties [32], Chronbach’s α in the current study was .90.

Statistical analyses

Descriptive statistics on age, gender, education level and diagnosis were compiled at baseline. Distribution of scores on the EQ-5D dimensions were calculated in percentages at baseline and at end of treatment and analysed using a non-parametric test of trends developed by Cuzick, similar to the Wilcoxon rank-sum test [33]. Mean scores and standard deviations at baseline and end of treatment were calculated. Change (Δ) during treatment was calculated for the BAI, the BDI-II, the EQ-5D values, and the EQ VAS by subtracting score at end of treatment from baseline score. Effect sizes (ES) from baseline to end of treatment were calculated using Cohen’s d . Values $< .50$ are considered small, $\geq .50 < .80$ moderate, and $\geq .80$ large [34]. We also calculated the standardised response mean (SRM), defined as the mean change in score from baseline to end of treatment divided by the standard deviation of change in scores [35]. It is suggested that interpretation of the SRM should take correlation between scores at baseline and end of treatment into account. For example, $SRM > 0.8$ can be interpreted as large if this correlation $< .50$, moderate if correlation $> .50$ [36]. Agreement between the change scores on the four measures were also analysed with Spearman’s correlation. We interpreted Spearman’s correlation as weak if $r_s .0 - .39$, moderate if $r_s .40 - .69$, and strong if $r_s > .70$ [37].

Using the BAI and the BDI-II, the patients were classified according to treatment response. With a minimum score of 14 on the BDI-II for depression patients and 16 on the BAI for anxiety patients at baseline, the following classification was used: Patients were classified as “Deteriorated” if their scores increased by 9 points or more from baseline to end of treatment. If the change was less than 9 points in either direction, they were classified as “Unchanged”. If the scores decreased by 9 points or more patients were classified as “Improved”. Finally, patients were classified as “Recovered” if their score decreased by 9 points or more and their final score was below clinical threshold (i.e. 14 for the BDI-II and 16 for the BAI) [38, 39].

We ran ROC curve analyses to determine how well the EQ-5D value scores could classify patients according to the clinical criteria of the BDI-II and the BAI: Recovered versus Improved, Recovered versus Unchanged, and Improved versus Unchanged. This was done with both the BDI-II and the BAI for the total sample, and separately with the BDI-II for the patients with depression disorders, and with the BAI for patients with anxiety disorders. Using the EQ-5D value at end of treatment as classifier, we computed area under the curve (AUROC). AUROC was interpreted as $< .50$ useless test, $.51 - .69$ poor test, $.70 - .79$ fair test, $.80 - .89$ good test, $.90 - .99$ excellent test, 1.00 perfect test [40]. We also computed cut-off values for recovery using Youden’s index (J), which chooses the values with highest combined sensitivity and specificity [41].

Missing data in the study was typically low, > 5% on individual items for all measures. Generally accepted methods for handling missing data are applicable to the EQ-5D [6]. Missing data on individual items in the current study were replaced by weighted means, a method developed for treating missing data in depression cohorts [42]. All analyses were carried out using STATA 16.1[43]

Ethical considerations

All patients included in the study gave written, informed consent to participate. The study is classified as health service research under Norwegian regulation. The Norwegian Data Protection Agency has in such cases designated that treatment providers (i.e. hospitals) are responsible for proper data management. Data collection and security in the present study was managed by Diakonhjemmet Hospital, and approval of data handling was granted by Oslo University Hospital, approval number 2015/15606. The study was carried out in accordance with the principles of the Helsinki declaration.

Results

Characteristics of included patients ($N = 416$) at baseline are shown in Table 1. The study only recorded primary diagnoses, comorbidity was not recorded. The majority of patients had either a primary depression or anxiety diagnosis, the remaining patients were diagnosed with either mixed anxiety / depression, or adjustment disorder. The most prevalent single diagnoses were F32 Major depressive disorder, single episode ($n = 114$, 26.8 %), F 33 Major depressive disorder, recurrent ($n = 97$, 22.8 %), and F 41.1 Generalised anxiety disorder ($n = 86$, 20.2 %).

Table 1
Demographic characteristics and diagnoses of patients at baseline (*N* = 416)

	Mean	SD	<i>n</i>	%
Age, years	37.66	10.65		
Gender				
Female			299	71.88
Male			117	28.13
Education				
Primary / Secondary			70	17.16
Higher education ≤ 4 yrs			151	37.01
Higher education > 4 yrs			187	45.83
Primary diagnosis				
Depression disorder			216	51.92
Anxiety disorder			161	38.70
Mixed anxiety / depression			24	6.77
Adjustment disorder			15	3.61

Change in depression, anxiety and the EQ-5D during treatment

Of the 216 patients with depression diagnoses, 146 (67.59 %) were “Recovered” at end of treatment, 31 (14.35 %) were “Improved”, and 39 were (18.05 %) were “Unchanged”. Of the 161 patients with anxiety disorder diagnoses, 109 (67.70 %) were “Recovered” at end of treatment, 14 (8.69 %) were “Improved”, and 38 were (23.60 %) were “Unchanged”. Overall, two patients in the sample were “Deteriorated” on the BAI at end of treatment, both were diagnosed with adjustment disorder. Four patients were “Deteriorated” on the BDI-II, three of which were diagnosed with adjustment disorder, and one with anxiety disorder. No patients with anxiety diagnoses were “Deteriorated” on the BAI at end of treatment, and no patients with depression diagnoses were “Deteriorated” on the BDI-II at end of treatment.

Table 2 shows the distribution of scores on the EQ-5D dimensions at baseline, and after end of treatment. All dimensions had at least some patients reporting problems at baseline. Cuzick’s non-parametric test of trends showed that all dimensions saw significant improvement from baseline to end of treatment [33]. The symptom scores reported on the BDI-II and the BAI at baseline in Table 3 indicate moderate levels of depression and anxiety. Patients saw a marked improvement in symptoms over the observation period. Cohen’s *d* was > .80 on all measures from baseline to end of treatment. Similarly, all SRM showed values

> .80 on all instruments. Correlation between baseline scores and scores at end of treatment were < .50 on the BDI-II ($r_s = .39$), EQ-5D utility ($r_s = .34$), and the EQ-VAS ($r_s = .31$), but > .50 on the BAI ($r_s = .51$). This indicates that the SRM was large for the BDI-II, EQ-5D utility, and the EQ VAS, whilst moderate for the BAI.

Table 2
Distribution of EQ-5D dimensions as reported by patients (N= 416)

		Baseline		End of treatment		p value
		n	%	n	%	
Mobility						
	No problems	323	78.59	364	88.35	< .001
	Slight problems	62	15.09	39	9.47	
	Moderate problems	20	4.87	9	2.18	
	Severe problems	6	1.46	.	.	
	Unable to walk about	.	.	.	.	
Self-care						
	No problems	350	85.37	398	96.60	< .001
	Slight problems	52	12.68	11	2.67	
	Moderate problems	6	1.46	2	0.49	
	Severe problems	2	0.49	1	0.49	
	Unable to wash or dress	.	.	.	.	
Usual activities						
	No problems	83	20.19	258	62.93	< .001
	Slight problems	161	39.17	111	27.07	
	Moderate problems	113	27.49	35	8.54	
	Severe problems	50	12.17	6	1.46	
	Unable to do usual activities	4	0.97	.	.	
Pain / discomfort						
	No problems	93	22.63	206	50.00	< .001
	Slight problems	177	43.07	151	36.65	
	Moderate problems	113	27.49	45	10.92	
	Severe problems	24	5.84	7	1.70	
	Extreme pain or discomfort					

Note. Proportion of patients reporting the various levels of severity on the EQ-5D dimensions at baseline, and at end of treatment. The *P*-values denote significance of a non-parametric test of trends across ordered groups, developed by Cuzick, similar to the Wilcoxon rank-sum test [33].

		Baseline		End of treatment		<i>p</i> value
		4	0.97	3	0.73	
Anxiety / depression						
No problems		13	3.17	160	38.83	< .001
Slight problems		106	25.85	187	44.39	
Moderate problems		179	43.66	53	12.86	
Severe problems		105	25.61	11	2.67	
Extremely anxious or depressed		7	1.71	1	0.24	
Note. Proportion of patients reporting the various levels of severity on the EQ-5D dimensions at baseline, and at end of treatment. The <i>P</i> -values denote significance of a non-parametric test of trends across ordered groups, developed by Cuzick, similar to the Wilcoxon rank-sum test [33].						

Table 3
Instrument scores at baseline and end of treatment with ES and SRM (*N*= 416)

	Baseline		End of treatment		<i>d</i>	SRM
	<i>Mean</i>	<i>SD</i>	<i>Mean</i>	<i>SD</i>		
Anxiety (BAI)	18.48	10.27	6.49	6.47	1.39	1.35
Depression (BDI-II)	26.42	8.77	10.13	8.84	1.84	1.67
EQ-5D value	.630	.189	.816	.153	1.07	.93
EQ VAS	54.58	17.13	74.71	14.80	1.25	1.06
Note. Abbreviations: BAI, the Beck Anxiety Inventory; BDI-II, the Beck Depression Inventory-II; ES, Effect Size (reported in Cohen's <i>d</i>); SRM, Standardised response mean.						

Correlation of change scores

Spearman's rank order correlations are shown in Table 4. Note that the BAI and the BDI-II indicate worse health status with higher scores, whereas the reverse is true for the EQ-5D value and the EQ VAS. The EQ-5D value change showed moderate correlations with both the BDI-II, the BAI, and the EQ VAS. A weak correlation was seen between the EQ VAS and the BAI.

Table 4
Spearman's correlation of change scores (*N*= 416)

	BAI Δ	BDI-II Δ	EQ-5D value Δ
BAI Δ			
BDI-II Δ	.48		
EQ-5D value Δ	– .41	– .48	
EQ VAS Δ	– .32	– .56	.51
Note. Change scores calculated by subtracting the score at end of treatment from the score at baseline. Abbreviations: BAI, the Beck Anxiety Inventory; BDI-II, the Beck Depression Inventory-II. Spearman's correlation 0 – .39 are considered weak, .40 – .69 moderate [37].			

ROC curve analysis

For the total sample, the ROC curve analysis showed that the EQ-5D value consistently distinguished between “Recovered” and “Improved” or “Unchanged” patients according the BDI-II or BAI, AUROC ranging from .72 – .84 (Table 5). The AUC did not adequately distinguish between “Improved” and “Unchanged” on either measure, AUROC ranged from .49 – .61.

Table 5

Area under the receiver operating characteristic curve (AUROC) using non-parametric ROC analysed (N=416)

		BDI-II				BAI			
		n	AUROC	SE	95 % CI	n	AUROC	SE	95 % CI
Overall									
	Recovered vs. Unchanged	329	0.81	.032	(0.75–0.88)	215	0.82	.039	(0.75–0.90)
	Recovered vs. Improved	314	0.78	.035	(0.71–0.85)	210	0.72	.061	(0.60–0.84)
	Improved vs. Unchanged	121	0.52	.052	(0.48–0.68)	49	0.64	.079	(0.49–0.80)
Depression diagnoses									
	Recovered vs. Unchanged	184	0.80	.045	(0.71–0.88)				
	Recovered vs. Improved	176	0.75	.047	(0.65–0.84)				
	Improved vs. Unchanged	68	0.61	.070	(0.47–0.75)				
Anxiety diagnoses									
	Recovered vs. Unchanged					147	0.83		(0.71–0.95)
	Recovered vs. Improved					123	0.84		(0.70–0.97)
	Improved vs. Unchanged					52	0.53		(0.29–0.77)

Note. Area under the curve (AUROC) reported for receiver operating analyses. The BAI and the BDI-II were used as classifiers of whether patients were “Recovered”, “Improved”, or “Unchanged” at end of treatment. Analyses were run using the BAI and the BDI-II for the whole sample, using the BDI-II for only the patients with depression diagnoses, and using the BAI for only the patients with anxiety diagnoses. Abbreviations: BAI, the Beck Anxiety Inventory; BDI-II, the Beck Depression Inventory-II.

The same pattern repeated when patients scores were analysed according to diagnoses. For patients with depression, the AUC was excellent when distinguishing between “Recovered” and “Unchanged” (.80) and acceptable distinguishing “Recovered” from “Improved” (.75), but ineffective separating “Improved” and “Unchanged” (.61). For patients with anxiety, the AUC showed excellent classification for both “Recovered” versus “Unchanged” (.83) and “Recovered” versus “Improved” (.84). The test did not distinguish between “Improved” versus “Unchanged” (.53). Youden’s index indicated that an EQ-5D value of .768 had the highest combined sensitivity and specificity when identifying recovered patients. The value was the same for both depression and anxiety (Table 6).

Table 6

The central range of operating characteristics of the EQ-5D value post-treatment for identifying recovered versus non-recovered patients (*N*= 416)

EQ-5D cut-off	Sensitivity	Specificity	<i>J</i>	Correctly classified
Depression				
.740	84.72 %	62.69 %	0.47	77.73
.750	81.25 %	62.69 %	0.44	75.36
.768	80.56 %	64.18 %	0.45	75.36
.819	74.31 %	67.16 %	0.41	72.04
.827	74.31 %	68.66 %	0.43	72.51
Anxiety				
.740	84.75 %	80.00 %	0.65	83.76
.750	83.70 %	80.00 %	0.64	82.91
.768	83.70 %	84.00 %	0.68	83.76
.819	63.04 %	84.00 %	0.47	67.52
.827	60.87 %	84.00 %	0.45	65.81
Note. <i>J</i> = Youden’s index. Depression and Anxiety recovery measured and classified using the BDI-II and the BAI, respectively.				

Discussion

Our aim was to explore the responsiveness of the EQ-5D in patients receiving treatment for depression and anxiety. This was done by comparing change in the EQ-5D to change in the disorder-specific measures BDI-II and BAI. We hypothesised that the EQ-5D should show magnitude of change as the BDI-II and BAI during treatment. The ES was large ($d > .80$) for all measures, ranging from Cohen’s d 1.07–1.84. For the SRM, which accounts for variability in treatment response by dividing change scores by the

standard deviation of change scores, the BDI-II, the EQ-5D value and the EQ VAS all showed large magnitude of change. The BAI showed moderate magnitude of change on the SRM when accounting for its higher correlation between baseline and end of treatment scores. Furthermore, the EQ-5D value change scores showed moderate correlation with the BDI-II and the BAI change scores. The hypothesis that the EQ-5D should show similar magnitude of change as the condition-specific measures during treatment thus seems confirmed.

We then examined if the EQ-5D utility could correctly classify patients deemed as “Recovered” according to the condition-specific measures. Results from the ROC analyses indicate that this was the case: AUROC were from fair to good on all analyses when distinguishing “Recovered” patients from “Improved” or “Unchanged”. This was true for the total sample (AUROC .72 – .82), for patients with depression (AUROC .75 and .80), and for patients with anxiety (AUROC .83 and .84). In a similarly consistent pattern, the EQ-5D showed poor ability to distinguish between “Improved” and “Unchanged” patients for the total sample, for depression, and for anxiety, (AUROC .52 – .61). The ability of the EQ-5D to consistently identify recovered patients indicates that our second hypothesis was confirmed. We also calculated Youden’s index, as this may be informative for clinicians and serve as a reference for future research. For recovery from both depression and anxiety, cut-off point as defined by highest combined sensitivity and specificity was an EQ-5D utility $\geq .768$ at end of treatment.

Data on the responsiveness of the five-level version of the EQ-5D in mental health is limited, though cross-sectional measures have indicated moderate to good correlation with condition-specific measures [10]. Comparing to the three-level version, one study found moderate responsiveness to anxiety disorders. Similar to the present study, patients were classified as having either “more”, “constant”, or “less anxiety” according to the BAI. T-tests showed significant differences in change scores for the EQ-5D value and the EQ VAS. However, that study found that the SRM were moderate to small, and ES were large for the EQ-5D value only when patients were deteriorated [17].

Reviews of the literature on the three-level version have indicated reasonable responsiveness in depression and anxiety [9], suggesting that the five-level may have similar properties. One recent study compared the responsiveness of the three-level and five-level versions of Anxiety/depression dimension for mental health patients. Although the five-level version was found to be more responsive, both showed limited ability to capture changes in mental health [18]. The Anxiety/depression dimension did show significant change from baseline to end of treatment in the present study. Future research may determine if it is useful as a standalone tool.

A previous cross-sectional study did find that the EQ-5D value could screen for depression and anxiety in patients with type 2 diabetes [19]. In the present study, the EQ-5D value showed similar performance in a longitudinal design in patients with depression and anxiety as primary diagnoses. That the EQ-5D value may perform better than the Anxiety / depression dimension alone is perhaps reasonable, as it may better capture the wide-ranging impact of depression and anxiety on health and quality of life [4, 5].

The EQ-5D is increasingly used when evaluating health status in surveys and clinical trials [6], and decision-making bodies recommend its use in evaluating health technologies [7, 44]. Demonstrating its validity in diverse patient groups is therefore essential for assisting sound decision-making when allocating health care resources. In this study, the EQ-5D showed good responsiveness to change for patients with depression and anxiety. This suggests that the EQ-5D can be a valid and useful tool for evaluating impact of disease and benefit of treatment for these patients, for instance through estimating QALYs. It also suggests that the EQ-5D can be useful in clinical setting, such as evaluating treatment outcomes.

Strengths and limitations

The main strength of the study is adding to a limited evidence-base concerning the responsiveness of the five-level version of the EQ-5D in patients with depression and anxiety. The study included a fairly large clinical sample who were assessed and diagnosed by clinical psychologists before entering treatment. We can thus be reasonably certain of the clinical characteristics of the sample. The study took part in a national health service clinic, suggesting that these patients are somewhat representative of clinical populations with depression and anxiety in Norway. The patients saw substantial treatment gains as reflected by the large ES and SRM, which gave an opportunity for evaluating the ability of the EQ-5D to identify recovered patients.

Several limitations to the study have to be considered. The study only included patients who completed treatment, and treatment gains were large. The study could therefore not evaluate the ability of the EQ-5D to detect smaller changes, that still may be of importance to patients. A related limitation is that the large rate of recovered patients in the study meant that “Unchanged” patients formed a small subgroup. The findings concerning the unchanged patients should be treated with caution. We also lack adequate data to determine if the EQ-5D would be equally responsive to deterioration as improvement during treatment. The study also lacked data on comorbidity.

The current study uses the UK value set for converting to EQ-5D value scores, as there is currently no Norwegian value set available. Choice of value sets has shown to influence the estimation of QALYs, which suggests that it would be useful to replicate the present findings when a Norwegian value set is available [13].

As new measures of health status become available, such as the Recovering Quality of Life (ReQoL) or capability-oriented instruments, it will be important to compare and contrast these against the EQ-5D to judge which instrument is best suited for patients with depression and anxiety [45, 46]. There is evidence that a wide range of outcomes that are important to patients with mental health problems are not adequately captured by commonly used instruments [5, 8]. Further research is needed to assess whether the EQ-5D could reflect key changes in a wider range of outcomes [5], or if other instruments or bolt-on dimensions may be better for capturing psycho-social factors of importance to patients [47].

Conclusion

The findings in this study suggest that the EQ-5D may be responsive to change in health status for patients receiving treatment for depression and anxiety. The EQ-5D showed similar magnitude of change as the condition-specific measures and was also able to consistently identify patients who had recovered from depression and anxiety. Responsiveness of the EQ-5D is likely sensitive to context, and these findings should be replicated in other samples. Still, these findings suggest that the EQ-5D may be a useful tool for evaluating outcomes of treatment for patients with depression and anxiety.

Declarations

Funding

The study was primarily sponsored by Diakonhjemmet Hospital, with additional funding from the Southern and Eastern Norway Regional Health Authority, and Stiftelsen Dam (2018/FO201448), a not for profit trust that funds health research and innovation projects.

Conflict of interest

None declared.

Availability of data material

The patient data used for this study is not readily available as the patients have not given consent for use or distribution beyond the research at Diakonhjemmet Hospital. Inquiries can be directed to kenneth.sandin@diakonsyk.no.

Code availability

Any inquiry can be directed to kenneth.sandin@diakonsyk.no

Authors' contribution

All authors contributed to the conceptualisation and design of the study. KS led the writing of the manuscript and is the principal author of the funding application. GS contributed to conceptualisation, analyses, and writing. RGHG, KO, MTB, and SER contributed to design of study and intervention, data management, and writing. OH is the project manager and contributed to design, analyses and writing. All authors read and approved the final manuscript.

Ethics approval

This study was approved as a health service study by the Norwegian Data Protection Authority. The data used in the present study is part of ongoing routine data collection, and no further approval is needed beyond consent from the individual patient. Data collection and security in the present study was

managed by Diakonhjemmet Hospital, and approval of data handling was granted by Oslo University Hospital, approval number 2015/15606.

Consent for publication

All participants gave written, informed consent for use of data for research and publication.

Acknowledgement

The authors would like to thank the patients, next of kin, and user representatives for their participation in the study, and for their valuable feedback. We would also like to thank the staff at the Division of Mental Health and Substance Abuse at Diakonhjemmet Hospital.

References

1. OECD. Health at a Glance 2019: OECD Indicators. Paris: OECD Publishing; 2019.
2. Bloom DE, Cafiero ET, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S, Feigl AB, Gaziano T, Mowafi M, Pandya A, Prettner K, Rosenberg L, Seligman B, Stein AZ, Weinstein C. The Global Economic Burden of Noncommunicable Diseases. Geneva; 2011.
3. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJL, Vos T. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. *The Lancet*. 2013;382(9904):1575–86.
4. Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. *The Lancet Psychiatry*. 2016;3(2):171–8.
5. Chevance A, Ravaud P, Tomlinson A, Le Berre C, Teufer B, Touboul S, Fried EI, Gartlehner G, Cipriani A, Tran VT. Identifying outcomes for depression that matter to patients, informal caregivers, and health-care professionals: qualitative content analysis of a large international online survey. *The Lancet Psychiatry*. 2020;7(8):692–702.
6. Devlin NJ, Parkin D, Janssen B. *Methods for Analysing and Reporting EQ-5D Data*. Springer; 2020.
7. National Institute for Health and Clinical Excellence. *Guide to the processes of technology appraisal*. 2018.
8. Cuijpers P. Targets and outcomes of psychotherapies for mental disorders: an overview. *World Psychiatry*. 2019;18:276–85.
9. Brazier J, Connell J, Papaioannou D, Mukuria C, Mulhern B, Peasgood T, Jones ML, Paisley S, O'Cathain A, Barkham M, Knapp M, Byford S, Gilbody S, Parry G, *A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures*. Health Technology Assessment, 2014. **18**(34): p. vii-viii, xiii-xxv, 1-188.

10. Feng YS, Kohlmann T, Janssen MF, Buchholz I. *Psychometric properties of the EQ-5D-5L: a systematic review of the literature*. Qual Life Res, 2020.
11. Mihalopoulos C, Chen G, Iezzi A, Khan MA, Richardson J. Assessing outcomes for cost-utility analysis in depression: comparison of five multi-attribute utility instruments with two depression-specific outcome measures. Br J Psychiatry. 2014;205(5):390–7.
12. Engel L, Chen G, Richardson J, Mihalopoulos C. The impact of depression on health-related quality of life and wellbeing: identifying important dimensions and assessing their inclusion in multi-attribute utility instruments. Qual Life Res. 2018;27(11):2873–84.
13. Camacho EM, Shields G, Lovell K, Coventry PA, Morrison AP, Davies LM. A (five-)level playing field for mental health conditions?: exploratory analysis of EQ-5D-5L-derived utility values. Qual Life Res. 2018;27(3):717–24.
14. Streiner DL, Norman GR, Cairney J. Health Measurement Scales: A practical guide to their development and use. 5th ed. Oxford: Oxford University Press; 2014.
15. Jacobson NS, Roberts LJ, Berns SB, McGlinchey JB. Methods for defining and determining the clinical significance of treatment effects: description, application, and alternatives. J Consult Clin Psychol. 1999;67(3):300–7.
16. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102–9.
17. König HH, Bjørn A, Günther OH, Matschinger H, Heinrich S, Riedel-Heller SG, Angermeyer MC, Roick C. *Validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with anxiety disorders*. Health Qual Life Outcomes, 2010. 8(47).
18. Crick K, Al Sayah F, Ohinmaa A, Johnson JA. Responsiveness of the anxiety/depression dimension of the 3- and 5-level versions of the EQ-5D in assessing mental health. Qual Life Res. 2018;27(6):1625–33.
19. Al Sayah F, Ohinmaa A, Johnson JA. Screening for Anxiety and Depressive Symptoms in Type 2 Diabetes Using Patient-Reported Outcome Measures: Comparative Performance of the EQ-5D-5L and SF-12v2. MDM Policy & Practice, 2018. 3(2): p. 238146831879936.
20. Lecrubier T, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH, Janavs J, Dunbar GC. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. European Psychiatry. 1997;12(5):224–31.
21. Beck AT, Steer RA, Brown GK. Manual for Beck Depression Inventory II (BDI-II). San Antonio: Psychology Corporation; 1996.
22. Beck AT, Steer RA. Manual for the Beck anxiety inventory. San Antonio: Psychological Corporation; 1990.
23. WHO. The International Classification of Diseases-10 (ICD-10). Geneva: World Health Organisation; 1992.
24. Dobson KS, Dozois DJA. Handbook of Cognitive Behavioral Therapies. Fourth ed.: Guilford Press; 2019.

25. Wells A. Metacognitive therapy for anxiety and depression. New York:: Guilford Press; 2011.
26. Gjengedal RGH, Reme S, Osnes K, Lagerveld S, Blonk R, Sandin K, Berge T, Hjemdal O. *Work-Focused Treatment for Common Mental Disorders: An observational study comparing an intervention group with a waiting list control group*. WORK: A Journal of Prevention, Assessment, and Rehabilitation, 2020. 6(3): p. 657–667.
27. Moen Hansen T, Helland Y, Augestad LA, Rand K, Stavem K, Garratt A. Elicitation of Norwegian EQ-5D-5L values for hypothetical and experience-based health states based on the EuroQol Valuation Technology (EQ-VT) protocol. BMJ Open. 2020;10:e034683.
28. National Institute for Health and Clinical Excellence. *Position statement on use of the EQ-5D-5L value set for England*. 2019 [cited 2020 10 Jan]; Available from: <https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l>.
29. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–15.
30. Stavem K, Augestad LA, Kristiansen IS, Rand K. General population norms for the EQ-5D-3 L in Norway: comparison of postal and web surveys. Health Qual Life Outcomes. 2018;16(1):204.
31. Wang YP, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. Braz J Psychiatry. 2013;35(4):416–31.
32. Beck AT, Epstein N, Brown GK, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893–7.
33. Cuzick J. A Wilcoxon-type test for trend. STATISTICS IN MEDICINE. 1985;4:87–90.
34. Cohen J. Statistical power analyses for the social sciences. Hillsdale: Lawrence Erlbaum Associates; 1988.
35. Liang M. *Longitudinal Construct Validity Establishment of Clinical Meaning in Patient Evaluative Instruments*. Medical Care, 2000. 38(9).
36. Middel B, van Sonderen E. *Statistical significant change versus relevant or important change in (quasi) experimental design: some conceptual and methodological problems in estimating magnitude of intervention-related change in health services research*. International Journal of Integrated Care, 2002. 2.
37. Akoglu H. User's guide to correlation coefficients. Turk J Emerg Med. 2018;18(3):91–3.
38. Gillis MM, Haaga D, Ford GT. Normative values for the Beck Anxiety Inventory, Fear Questionnaire, Penn State Worry Questionnaire, and Social Phobia and Anxiety Inventory. Psychol Assess. 1995;7(4):450–5.
39. Seggar LB, Lambert MJ, Hansen NB. Assessing clinical significance: Application to the beck depression inventory. Behav Ther. 2002;33(2):253–69.
40. Hanley JA, McNeil BJ. The Meaning and Use of the Area under a Receiver Operating Characteristic (ROC) Curve. Radiology. 1982;143:29–36.

41. Youden WJ. Index for rating diagnostic tests. *Cancer*. 1950;3(1):33–5.
42. Gale T, Hawley C. A model for handling missing items on two depression rating scales. *International clinical psychopharmacology*. 2001;16(4):205–14.
43. StataCorp.. *Stata Statistical Software: Release 16*. College Station: StataCorp LLC; 2019.
44. National Institute of Public Health. *Fremskaffing av EQ-5D vektor og normative data for helseøkonomiske evalueringer - prosjektbeskrivelse. (English: Acquisition of EQ-5D weights and normative data for health economic evaluations – project description)*.. 2019 [cited 2020 27 Sept]; Available from: <https://www.fhi.no/cristin-prosjekter/aktiv/fremskaffing-av-eq-5d-vektor-og-normative-data-for-helseokonomiske-evaluering/>.
45. Keetharuth AD, Brazier J, Connell J, Bjorner JB, Carlton J, Buck ET, Ricketts T, McKendrick K, Browne J, Croudace T, Barkham M. Recovering Quality of Life (ReQoL): a new generic self-reported outcome measure for use with people experiencing mental health difficulties†. *The British Journal of Psychiatry*. 2018;212:42–9.
46. Mitchell PM, Al-Janabi H, Byford S, Kuyken W, Richardson J, Iezzi A, Coast J. Assessing the validity of the ICECAP-A capability measure for adults with depression. *BMC Psychiatry*. 2017;17(1):46.
47. Chen G, Olsen JA. Filling the psycho-social gap in the EQ-5D: the empirical support for four bolt-on dimensions. *Qual Life Res*. 2020;29(11):3119–29.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [StrobechecklistResponsivenessEQ5D.pdf](#)